Amarin Sues FDA Over Vascepa Market Exclusivity Denial

Amarin Sues FDA Over Vascepa Market Exclusivity Denial

Amarin Corp. PLC sued the U.S. Food and Drug Administration in Washington, D.C., federal court Thursday, alleging the regulator wrongly denied its bid for a market exclusivity period for high blood fat treatment Vascepa, exposing it to possible patent ...read more

  • Tags: